Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy

Katalin Tóth, Tamás Bdi, Ádám Kiss, Manna Temesvári, Edit Háfra, Andrea Nagy, Zsuzsa Szever, K. Monostory

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aim: Since prominent role in valproate metabolism is assigned to CYP2C9 in pediatric patients, the association between children's CYP2C9-status and serum valproate concentrations or dose-requirements was evaluated. Materials & Methods: The contribution of CYP2C9 genotype and CYP2C9 expression in children (n = 50, Caucasian) with epilepsy to valproate pharmacokinetics was analyzed. Results: Valproate concentrations were significantly lower in normal expressers with CYP2C9∗1/∗1 than in low expressers or in patients carrying polymorphic CYP2C9 alleles. Consistently, the dose-requirement was substantially higher in normal expressers carrying CYP2C9∗1/∗1 (33.3 mg/kg vs 13.8-17.8 mg/kg, p <0.0001). Low CYP2C9 expression significantly increased the ratio of poor metabolizers predictable from CYP2C9 genotype (by 46%). Conclusion: Due to the substantial downregulation of CYP2C9 expression in epilepsy, inferring patients' valproate metabolizing phenotype merely from CYP2C9 genotype results in false prediction.

Original languageEnglish
Pages (from-to)199-207
Number of pages9
JournalPersonalized Medicine
Volume12
Issue number3
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Valproic Acid
Epilepsy
Genotype
Therapeutics
Cytochrome P-450 CYP2C9
Down-Regulation
Pharmacokinetics
Alleles
Pediatrics
Phenotype
Serum

Keywords

  • CYP2C9 expression
  • CYP2C9 genotype
  • CYPtest
  • cytochrome P450
  • epilepsy
  • pediatric patients
  • personalized medication
  • valproate therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy. / Tóth, Katalin; Bdi, Tamás; Kiss, Ádám; Temesvári, Manna; Háfra, Edit; Nagy, Andrea; Szever, Zsuzsa; Monostory, K.

In: Personalized Medicine, Vol. 12, No. 3, 01.06.2015, p. 199-207.

Research output: Contribution to journalArticle

Tóth, Katalin ; Bdi, Tamás ; Kiss, Ádám ; Temesvári, Manna ; Háfra, Edit ; Nagy, Andrea ; Szever, Zsuzsa ; Monostory, K. / Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy. In: Personalized Medicine. 2015 ; Vol. 12, No. 3. pp. 199-207.
@article{cfef25a61dfb45eebc1d1dc27b0a5dcf,
title = "Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy",
abstract = "Aim: Since prominent role in valproate metabolism is assigned to CYP2C9 in pediatric patients, the association between children's CYP2C9-status and serum valproate concentrations or dose-requirements was evaluated. Materials & Methods: The contribution of CYP2C9 genotype and CYP2C9 expression in children (n = 50, Caucasian) with epilepsy to valproate pharmacokinetics was analyzed. Results: Valproate concentrations were significantly lower in normal expressers with CYP2C9∗1/∗1 than in low expressers or in patients carrying polymorphic CYP2C9 alleles. Consistently, the dose-requirement was substantially higher in normal expressers carrying CYP2C9∗1/∗1 (33.3 mg/kg vs 13.8-17.8 mg/kg, p <0.0001). Low CYP2C9 expression significantly increased the ratio of poor metabolizers predictable from CYP2C9 genotype (by 46{\%}). Conclusion: Due to the substantial downregulation of CYP2C9 expression in epilepsy, inferring patients' valproate metabolizing phenotype merely from CYP2C9 genotype results in false prediction.",
keywords = "CYP2C9 expression, CYP2C9 genotype, CYPtest, cytochrome P450, epilepsy, pediatric patients, personalized medication, valproate therapy",
author = "Katalin T{\'o}th and Tam{\'a}s Bdi and {\'A}d{\'a}m Kiss and Manna Temesv{\'a}ri and Edit H{\'a}fra and Andrea Nagy and Zsuzsa Szever and K. Monostory",
year = "2015",
month = "6",
day = "1",
doi = "10.2217/pme.14.82",
language = "English",
volume = "12",
pages = "199--207",
journal = "Personalized Medicine",
issn = "1741-0541",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy

AU - Tóth, Katalin

AU - Bdi, Tamás

AU - Kiss, Ádám

AU - Temesvári, Manna

AU - Háfra, Edit

AU - Nagy, Andrea

AU - Szever, Zsuzsa

AU - Monostory, K.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Aim: Since prominent role in valproate metabolism is assigned to CYP2C9 in pediatric patients, the association between children's CYP2C9-status and serum valproate concentrations or dose-requirements was evaluated. Materials & Methods: The contribution of CYP2C9 genotype and CYP2C9 expression in children (n = 50, Caucasian) with epilepsy to valproate pharmacokinetics was analyzed. Results: Valproate concentrations were significantly lower in normal expressers with CYP2C9∗1/∗1 than in low expressers or in patients carrying polymorphic CYP2C9 alleles. Consistently, the dose-requirement was substantially higher in normal expressers carrying CYP2C9∗1/∗1 (33.3 mg/kg vs 13.8-17.8 mg/kg, p <0.0001). Low CYP2C9 expression significantly increased the ratio of poor metabolizers predictable from CYP2C9 genotype (by 46%). Conclusion: Due to the substantial downregulation of CYP2C9 expression in epilepsy, inferring patients' valproate metabolizing phenotype merely from CYP2C9 genotype results in false prediction.

AB - Aim: Since prominent role in valproate metabolism is assigned to CYP2C9 in pediatric patients, the association between children's CYP2C9-status and serum valproate concentrations or dose-requirements was evaluated. Materials & Methods: The contribution of CYP2C9 genotype and CYP2C9 expression in children (n = 50, Caucasian) with epilepsy to valproate pharmacokinetics was analyzed. Results: Valproate concentrations were significantly lower in normal expressers with CYP2C9∗1/∗1 than in low expressers or in patients carrying polymorphic CYP2C9 alleles. Consistently, the dose-requirement was substantially higher in normal expressers carrying CYP2C9∗1/∗1 (33.3 mg/kg vs 13.8-17.8 mg/kg, p <0.0001). Low CYP2C9 expression significantly increased the ratio of poor metabolizers predictable from CYP2C9 genotype (by 46%). Conclusion: Due to the substantial downregulation of CYP2C9 expression in epilepsy, inferring patients' valproate metabolizing phenotype merely from CYP2C9 genotype results in false prediction.

KW - CYP2C9 expression

KW - CYP2C9 genotype

KW - CYPtest

KW - cytochrome P450

KW - epilepsy

KW - pediatric patients

KW - personalized medication

KW - valproate therapy

UR - http://www.scopus.com/inward/record.url?scp=84930482445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930482445&partnerID=8YFLogxK

U2 - 10.2217/pme.14.82

DO - 10.2217/pme.14.82

M3 - Article

AN - SCOPUS:84930482445

VL - 12

SP - 199

EP - 207

JO - Personalized Medicine

JF - Personalized Medicine

SN - 1741-0541

IS - 3

ER -